Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

This will remain unchanged with GSK continuing to give Innoviva its cut of sales on Trelegy, Relvar and Anoro respiratory products. Together these products generated sales of almost $2.5 billion ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, ...

has promised to improve drug research productivity by narrowing GSK's focus to key areas such as HIV and respiratory medicine. Her immediate priority, however, is the launch of three new products.

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

Cantor said it sees the company’s royalty stream from GSK respiratory products generating $1B+ over the next five years and ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

GSK royalties are a major revenue source, but declining sales due to competition from newer products may impact future earnings. Innoviva's financial health is at risk due to its reliance on ...